mianserin has been researched along with Abnormalities, Drug-Induced in 6 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicenter, observational prospective cohort study addresses the risk associated with exposure to mirtazapine during pregnancy." | 7.81 | Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. ( Arnon, J; Buclin, T; Clementi, M; Eleftheriou, G; Kaplan, YC; Klinger, G; Malm, H; Maňáková, E; Merlob, P; Panchaud, A; Pistelli, A; Rothuizen, LE; Stephens, S; Te Winkel, B; Winterfeld, U, 2015) |
| "Mirtazapine is a novel piperazinoazepine antidepressant, unrelated to any known class of antidepressants." | 5.33 | Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. ( De Santis, M; Diav-Citrin, O; Djulus, J; Einarson, A; Einarson, TR; Kennedy, D; Koren, G; Shakir, S; Voyer Lavigne, S; Wilton, L, 2006) |
| "This multicenter, observational prospective cohort study addresses the risk associated with exposure to mirtazapine during pregnancy." | 3.81 | Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study. ( Arnon, J; Buclin, T; Clementi, M; Eleftheriou, G; Kaplan, YC; Klinger, G; Malm, H; Maňáková, E; Merlob, P; Panchaud, A; Pistelli, A; Rothuizen, LE; Stephens, S; Te Winkel, B; Winterfeld, U, 2015) |
| "Mirtazapine is a new antidepressant used in last years, however experience with it during pregnancy is unsatisfactory on the present." | 3.76 | Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test. ( Hubickova, L; Kostalova, J; Manakova, E; Zemanova, Z, 2010) |
| "Mirtazapine is a novel piperazinoazepine antidepressant, unrelated to any known class of antidepressants." | 1.33 | Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. ( De Santis, M; Diav-Citrin, O; Djulus, J; Einarson, A; Einarson, TR; Kennedy, D; Koren, G; Shakir, S; Voyer Lavigne, S; Wilton, L, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smit, M | 1 |
| Wennink, H | 1 |
| Heres, M | 1 |
| Dolman, KM | 1 |
| Honig, A | 1 |
| Winterfeld, U | 1 |
| Klinger, G | 1 |
| Panchaud, A | 1 |
| Stephens, S | 1 |
| Arnon, J | 1 |
| Malm, H | 1 |
| Te Winkel, B | 1 |
| Clementi, M | 1 |
| Pistelli, A | 1 |
| Maňáková, E | 2 |
| Eleftheriou, G | 1 |
| Merlob, P | 1 |
| Kaplan, YC | 1 |
| Buclin, T | 1 |
| Rothuizen, LE | 1 |
| Hubickova, L | 1 |
| Kostalova, J | 1 |
| Zemanova, Z | 1 |
| Yaris, F | 1 |
| Kadioglu, M | 1 |
| Kesim, M | 1 |
| Ulku, C | 1 |
| Yaris, E | 1 |
| Kalyoncu, NI | 1 |
| Unsal, M | 1 |
| Djulus, J | 1 |
| Koren, G | 1 |
| Einarson, TR | 1 |
| Wilton, L | 1 |
| Shakir, S | 1 |
| Diav-Citrin, O | 1 |
| Kennedy, D | 1 |
| Voyer Lavigne, S | 1 |
| De Santis, M | 1 |
| Einarson, A | 1 |
| Lennestål, R | 1 |
| Källén, B | 1 |
6 other studies available for mianserin and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Mirtazapine in pregnancy and lactation: data from a case series.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Tricyclic; Breast Feeding; Cohort Studies | 2015 |
Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents; Birth Weight; Case-Control Studies; Depre | 2015 |
Embryotoxicity of mirtazapine: a study using Chick Embryotoxicity Screening Test.
Topics: Abnormalities, Drug-Induced; Animals; Antidepressive Agents, Tricyclic; Chick Embryo; Depression; Do | 2010 |
Newer antidepressants in pregnancy: prospective outcome of a case series.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, | 2004 |
Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Abortion, Therapeutic; Adult; Antidepressive Age | 2006 |
Delivery outcome in relation to maternal use of some recently introduced antidepressants.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adrenergic Uptake Inhibitors; Antidepressive Age | 2007 |